JP2018510135A - RORγT阻害剤としての置換ピラゾール化合物及びその使用 - Google Patents
RORγT阻害剤としての置換ピラゾール化合物及びその使用 Download PDFInfo
- Publication number
- JP2018510135A JP2018510135A JP2017541959A JP2017541959A JP2018510135A JP 2018510135 A JP2018510135 A JP 2018510135A JP 2017541959 A JP2017541959 A JP 2017541959A JP 2017541959 A JP2017541959 A JP 2017541959A JP 2018510135 A JP2018510135 A JP 2018510135A
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- alkyl
- tetrahydro
- mmol
- cyclopropylbenzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UYPAVTZCVXPFAQ-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)Cc2c1c(-c(c(F)c1)ccc1C(O)=O)n[n]2C(c(c(C1CC1)ccc1)c1Cl)=O)=O Chemical compound CC(C)(C)OC(NC(CC1)Cc2c1c(-c(c(F)c1)ccc1C(O)=O)n[n]2C(c(c(C1CC1)ccc1)c1Cl)=O)=O UYPAVTZCVXPFAQ-UHFFFAOYSA-N 0.000 description 1
- BCSXUVZTKVXBSD-UHFFFAOYSA-N CC(CNCC1)C1N Chemical compound CC(CNCC1)C1N BCSXUVZTKVXBSD-UHFFFAOYSA-N 0.000 description 1
- XBIUTTXWWURGHK-UHFFFAOYSA-N CCc1n[n](C(c2c(C3CC3)cccc2Cl)=O)c(C2)c1CCC2NC(OC(C)(C)C)=O Chemical compound CCc1n[n](C(c2c(C3CC3)cccc2Cl)=O)c(C2)c1CCC2NC(OC(C)(C)C)=O XBIUTTXWWURGHK-UHFFFAOYSA-N 0.000 description 1
- IUAVAKAEXAAZAL-UHFFFAOYSA-N COC(C(CC1)Cc2c1c(I)n[n]2C(c1c(C2CC2)cccc1Cl)=O)=O Chemical compound COC(C(CC1)Cc2c1c(I)n[n]2C(c1c(C2CC2)cccc1Cl)=O)=O IUAVAKAEXAAZAL-UHFFFAOYSA-N 0.000 description 1
- BKWRLCIYMAYFPA-UHFFFAOYSA-N COC(c1cc(F)c(B(O)O)cc1)=O Chemical compound COC(c1cc(F)c(B(O)O)cc1)=O BKWRLCIYMAYFPA-UHFFFAOYSA-N 0.000 description 1
- AZHMCMMGUMQQHX-UHFFFAOYSA-N Ic1n[nH]c2c1CCCC2 Chemical compound Ic1n[nH]c2c1CCCC2 AZHMCMMGUMQQHX-UHFFFAOYSA-N 0.000 description 1
- ZKHDOWBUYPIKLV-UHFFFAOYSA-N O=C(c1c(C2CC2)cccc1Cl)Cl Chemical compound O=C(c1c(C2CC2)cccc1Cl)Cl ZKHDOWBUYPIKLV-UHFFFAOYSA-N 0.000 description 1
- ZNZLEMZPQHWNBS-UHFFFAOYSA-N O=C(c1c(C2CC2)cccc1Cl)[n](c1c2CCCC1)nc2I Chemical compound O=C(c1c(C2CC2)cccc1Cl)[n](c1c2CCCC1)nc2I ZNZLEMZPQHWNBS-UHFFFAOYSA-N 0.000 description 1
- HCYXHSKXTROMDM-UHFFFAOYSA-N O=C(c1c(C2CCC2)cccc1Cl)[n](c1c2CCCC1)nc2I Chemical compound O=C(c1c(C2CCC2)cccc1Cl)[n](c1c2CCCC1)nc2I HCYXHSKXTROMDM-UHFFFAOYSA-N 0.000 description 1
- RTLRDIAWRKKVFT-UHFFFAOYSA-N OC(c1c(C2CC2)cccc1Cl)=O Chemical compound OC(c1c(C2CC2)cccc1Cl)=O RTLRDIAWRKKVFT-UHFFFAOYSA-N 0.000 description 1
- OUGLIVSISBKMIE-UHFFFAOYSA-N OCC(CC1)Cc2c1c(-c(ccc(C(O)=O)c1)c1F)n[n]2C(c(c(C1CC1)ccc1)c1Cl)=O Chemical compound OCC(CC1)Cc2c1c(-c(ccc(C(O)=O)c1)c1F)n[n]2C(c(c(C1CC1)ccc1)c1Cl)=O OUGLIVSISBKMIE-UHFFFAOYSA-N 0.000 description 1
- GORQVVQHYIPFBT-UHFFFAOYSA-N OCC(CC1)Cc2c1c(I)n[n]2C(c1c(C2CC2)cccc1Cl)=O Chemical compound OCC(CC1)Cc2c1c(I)n[n]2C(c1c(C2CC2)cccc1Cl)=O GORQVVQHYIPFBT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114854P | 2015-02-11 | 2015-02-11 | |
| US62/114,854 | 2015-02-11 | ||
| PCT/US2016/017566 WO2016130818A1 (en) | 2015-02-11 | 2016-02-11 | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018510135A true JP2018510135A (ja) | 2018-04-12 |
| JP2018510135A5 JP2018510135A5 (cg-RX-API-DMAC7.html) | 2019-03-07 |
Family
ID=56614908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541959A Pending JP2018510135A (ja) | 2015-02-11 | 2016-02-11 | RORγT阻害剤としての置換ピラゾール化合物及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10221142B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3256450B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018510135A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016219183B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2975997A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016130818A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021527650A (ja) * | 2018-06-15 | 2021-10-14 | リアタ ファーマシューティカルズ インコーポレイテッド | IL−17およびRORγの阻害用のピラゾール化合物およびイミダゾール化合物 |
| JP2024501520A (ja) * | 2020-12-22 | 2024-01-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 新規ジアシルグリセリドo-アシルトランスフェラーゼ2阻害薬としてのテトラヒドロインダゾール誘導体の調製 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| JP2018531958A (ja) * | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
| US10287272B2 (en) | 2015-10-27 | 2019-05-14 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
| EP3368516B1 (en) * | 2015-10-27 | 2020-07-15 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| US10975057B2 (en) * | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | 6-aminopyridin-3-yl pyrazoles as modulators of RORgT |
| CA3121247A1 (en) | 2018-12-03 | 2020-06-11 | Board Of Regents, The University Of Texas System | Oligo-benzamide analogs and their use in cancer treatment |
| WO2021021951A1 (en) | 2019-07-29 | 2021-02-04 | Vanderbilt University | Wdr5-myc inhibitors |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505908A (ja) * | 2003-09-17 | 2007-03-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 縮合複素環式化合物 |
| WO2014028589A2 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014028591A2 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| JP2014509316A (ja) * | 2011-02-11 | 2014-04-17 | メルク・シャープ・アンド・ドーム・コーポレーション | RORγT阻害薬 |
| WO2015139621A1 (zh) * | 2014-03-18 | 2015-09-24 | 北京韩美药品有限公司 | 4-杂芳基取代的苯甲酸或苯甲酰胺类化合物 |
| JP2016141632A (ja) * | 2015-01-30 | 2016-08-08 | 第一三共株式会社 | 縮合二環式ヘテロ環誘導体 |
| WO2016128908A1 (en) * | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670447A (en) | 1983-08-22 | 1987-06-02 | Hoechst-Roussel Pharmaceuticals Inc. | Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles |
| GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| PT95899A (pt) | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| TW263508B (cg-RX-API-DMAC7.html) | 1991-02-12 | 1995-11-21 | Pfizer | |
| JP3414433B2 (ja) | 1993-03-01 | 2003-06-09 | 日本化薬株式会社 | 電子写真用トナー |
| US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
| DE19523446A1 (de) | 1995-06-28 | 1997-01-02 | Bayer Ag | Benzotriazole |
| AU6490396A (en) | 1995-07-14 | 1997-02-18 | Smithkline Beecham Corporation | Substituted-pent-4-ynoic acids |
| JPH11514969A (ja) | 1995-08-10 | 1999-12-21 | バイエル・アクチエンゲゼルシヤフト | ハロベンゾイミダゾール類および殺微生物剤としてのそれらの使用 |
| EP0882718B1 (en) | 1995-12-28 | 2005-08-31 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| HUP9903330A2 (hu) | 1996-11-19 | 2000-03-28 | Amgen Inc. | Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények |
| US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US6133290A (en) | 1998-07-31 | 2000-10-17 | Eli Lilly And Company | 5-HT1F agonists |
| CZ2001959A3 (cs) | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidiny jako inhibitory kinasy |
| US6348032B1 (en) | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
| WO2001012600A1 (en) | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| US7115750B1 (en) | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
| GB0117577D0 (en) | 2001-02-16 | 2001-09-12 | Aventis Pharm Prod Inc | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands |
| TWI239942B (en) | 2001-06-11 | 2005-09-21 | Dainippon Pharmaceutical Co | N-arylphenylacetamide derivative and pharmaceutical composition containing the same |
| MXPA04001014A (es) | 2001-08-03 | 2004-05-27 | Schering Corp | Novedosos inhibidores de la gama secretasa. |
| US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
| DE10229777A1 (de) | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| FR2845382A1 (fr) | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| JP4601038B2 (ja) | 2003-03-26 | 2010-12-22 | 第一三共株式会社 | インドリルマレイミド類 |
| NZ546611A (en) | 2003-09-18 | 2010-02-26 | Conforma Therapeutics Corp | Novel heterocyclic compounds as HSP90-inhibitors |
| SE0302760D0 (sv) | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| JP2007517052A (ja) | 2003-12-23 | 2007-06-28 | ノバルティス アクチエンゲゼルシャフト | 二環式ヘテロ環式p−38キナーゼ阻害剤 |
| EP1771204A4 (en) | 2004-07-01 | 2008-08-13 | Univ New York | COMPOSITIONS AND METHOD FOR MODULATING ROR-GAMMA-T |
| GT200500208A (es) | 2004-08-03 | 2006-03-02 | Indazoles ùtiles para tratar enfermedades cardiovasculares | |
| US20070010537A1 (en) | 2004-08-20 | 2007-01-11 | Kazumasa Hamamura | Fused pyramidine derivative and use thereof |
| CN101048407A (zh) | 2004-09-03 | 2007-10-03 | 普莱希科公司 | 双环杂芳基pde4b抑制剂 |
| SE0402762D0 (sv) | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| CN100516049C (zh) | 2004-11-16 | 2009-07-22 | 永信药品工业股份有限公司 | 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成 |
| AR051780A1 (es) | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| EP1828180A4 (en) | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| RU2008110908A (ru) | 2005-08-25 | 2009-09-27 | Шеринг Корпорейшн (US) | Производные имидазола в качестве функционально селективных агонистов альфа2с адренорецепторов |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| JP2009509928A (ja) | 2005-09-01 | 2009-03-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カリウムチャンネル開口剤としての新規ベンゾピラン誘導体 |
| JP4843040B2 (ja) | 2005-09-15 | 2011-12-21 | エフ.ホフマン−ラ ロシュ アーゲー | 肝カルニチンパルミトイルトランスフェラーゼのインヒビターとして有用な新規ヘテロ二環式誘導体 |
| AU2007214594B2 (en) | 2006-02-13 | 2010-11-11 | F. Hoffmann-La Roche Ag | Heterobicyclic sulfonamide derivatives for the treatment of diabetes |
| KR101411695B1 (ko) | 2006-02-17 | 2014-07-03 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물 |
| EP1984351A1 (en) | 2006-02-17 | 2008-10-29 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| JP4675801B2 (ja) | 2006-03-06 | 2011-04-27 | 日本メナード化粧品株式会社 | Ror活性化剤 |
| US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| US20080305169A1 (en) | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| EP2029550A2 (en) | 2006-06-01 | 2009-03-04 | Wyeth a Corporation of the State of Delaware | 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| WO2008003703A1 (en) | 2006-07-03 | 2008-01-10 | Biovitrum Ab (Publ) | Indoles as 5-ht6 modulators |
| TWI315304B (en) | 2006-08-31 | 2009-10-01 | Univ Taipei Medical | Indoline-sulfonamides compounds |
| WO2008045664A2 (en) | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Heterocyclic pde4 inhibitors as antiinflammatory agents |
| WO2008062740A1 (fr) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Composé azoté à anneaux fusionnés et son utilisation |
| US7799933B2 (en) | 2006-12-21 | 2010-09-21 | Hoffman-La Roche Inc. | Sulfonamide derivatives |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| MX2009011210A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| GB0708141D0 (en) | 2007-04-26 | 2007-06-06 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| AR068046A1 (es) | 2007-06-05 | 2009-11-04 | Schering Corp | Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| JP2010534665A (ja) | 2007-07-25 | 2010-11-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメチックス、それらの製造方法、医薬組成物、及びこれらの使用 |
| EP2197876A1 (en) | 2007-08-29 | 2010-06-23 | Glaxosmithkline LLC | Thiazole and oxazole kinase inhibitors |
| US7960376B2 (en) | 2007-09-14 | 2011-06-14 | Cara Therapeutics, Inc. | Benzo-fused heterocycles |
| RU2364597C1 (ru) | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
| US7960377B2 (en) | 2008-03-28 | 2011-06-14 | Cara Therapeutics, Inc. | Substituted pyridoxazines |
| EP2280946B1 (en) | 2008-06-05 | 2016-02-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
| WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| WO2009147188A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
| NZ589694A (en) | 2008-06-09 | 2012-05-25 | Sanofi Aventis | Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| WO2009149819A1 (en) | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| EP2298731A4 (en) | 2008-06-25 | 2011-09-21 | Takeda Pharmaceutical | AMIDE COMPOUND |
| WO2010017827A1 (en) | 2008-08-14 | 2010-02-18 | European Molecular Biology Laboratory | 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases |
| SI2344471T1 (sl) | 2008-10-02 | 2013-11-29 | Taisho Pharmaceutical Co., Ltd. | Derivat 7-piperidinoalkil-3,4-dihidrokvinolona |
| EP2181710A1 (en) | 2008-10-28 | 2010-05-05 | Phenex Pharmaceuticals AG | Ligands for modulation of orphan receptor-gamma (NR1F3) activity |
| WO2010050837A1 (ru) | 2008-10-28 | 2010-05-06 | Haskin Lev Yakovlevich | Ветроэнергетическая установка |
| WO2010057101A2 (en) | 2008-11-17 | 2010-05-20 | Schering Corporation | Compounds useful as hiv blockers |
| EP2367598B1 (en) | 2008-11-19 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of diacylglycerol acyltransferase |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
| CN102388054B (zh) | 2008-12-19 | 2015-03-04 | 西特里斯药业公司 | 噻唑并吡啶沉默调节蛋白调节剂的化合物 |
| TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| WO2010123139A1 (ja) | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
| RS53830B1 (sr) | 2009-04-30 | 2015-06-30 | Glaxo Group Limited | Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze |
| WO2010150837A1 (ja) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
| EP2459184A1 (en) | 2009-07-31 | 2012-06-06 | The Brigham and Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| US8119683B2 (en) | 2009-08-10 | 2012-02-21 | Taipei Medical University | Aryl substituted sulfonamide compounds and their use as anticancer agents |
| WO2011059839A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| AU2010330894A1 (en) | 2009-12-18 | 2012-07-05 | Janssen Pharmaceutica Nv | Substituted aminothiazolone indazoles as estrogen related receptor-aalpha modulators |
| US9260382B2 (en) | 2010-02-16 | 2016-02-16 | Uwm Research Foundation | Methods of reducing virulence in bacteria |
| CA2791738C (en) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Aryl imidazolyl compounds for the treatment of cancer |
| EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| EP2613781B1 (en) | 2010-09-08 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| HRP20151017T1 (hr) | 2010-09-08 | 2015-10-23 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida |
| WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| JP6063870B2 (ja) | 2010-11-08 | 2017-01-18 | ライセラ・コーポレイション | RORγ活性の阻害用のN−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 |
| KR20120063283A (ko) | 2010-12-07 | 2012-06-15 | 제일약품주식회사 | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| WO2012085168A1 (en) | 2010-12-22 | 2012-06-28 | Ludwig-Maximilians-Universität München | Organozinc complexes and processes for making and using the same |
| EP2511263A1 (en) | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| JP2014166961A (ja) | 2011-06-20 | 2014-09-11 | Dainippon Sumitomo Pharma Co Ltd | 新規インダゾール誘導体 |
| RU2014149136A (ru) | 2012-05-08 | 2016-07-10 | Мерк Шарп И Доум Корп. | ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| CA2871504C (en) | 2012-05-08 | 2020-07-21 | Merck Sharp & Dohme Corp. | Bicyclic sulfone compounds for inhibition of rorgamma activity and the treatment of disease |
| WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014026328A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
| TW201605797A (zh) | 2013-12-10 | 2016-02-16 | 葛蘭馬克製藥公司 | 作為ror伽馬調節物的雙環雜芳基化合物 |
| WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
-
2016
- 2016-02-11 CA CA2975997A patent/CA2975997A1/en not_active Abandoned
- 2016-02-11 AU AU2016219183A patent/AU2016219183B2/en not_active Expired - Fee Related
- 2016-02-11 JP JP2017541959A patent/JP2018510135A/ja active Pending
- 2016-02-11 WO PCT/US2016/017566 patent/WO2016130818A1/en not_active Ceased
- 2016-02-11 US US15/549,465 patent/US10221142B2/en active Active
- 2016-02-11 EP EP16749889.8A patent/EP3256450B1/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505908A (ja) * | 2003-09-17 | 2007-03-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 縮合複素環式化合物 |
| JP2014509316A (ja) * | 2011-02-11 | 2014-04-17 | メルク・シャープ・アンド・ドーム・コーポレーション | RORγT阻害薬 |
| WO2014028589A2 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014028591A2 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2015139621A1 (zh) * | 2014-03-18 | 2015-09-24 | 北京韩美药品有限公司 | 4-杂芳基取代的苯甲酸或苯甲酰胺类化合物 |
| JP2016141632A (ja) * | 2015-01-30 | 2016-08-08 | 第一三共株式会社 | 縮合二環式ヘテロ環誘導体 |
| WO2016128908A1 (en) * | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021527650A (ja) * | 2018-06-15 | 2021-10-14 | リアタ ファーマシューティカルズ インコーポレイテッド | IL−17およびRORγの阻害用のピラゾール化合物およびイミダゾール化合物 |
| US11993574B2 (en) | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
| JP7498122B2 (ja) | 2018-06-15 | 2024-06-11 | リアタ ファーマシューティカルズ インコーポレイテッド | IL-17およびRORγの阻害用のピラゾール化合物およびイミダゾール化合物 |
| JP2024501520A (ja) * | 2020-12-22 | 2024-01-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 新規ジアシルグリセリドo-アシルトランスフェラーゼ2阻害薬としてのテトラヒドロインダゾール誘導体の調製 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3256450A4 (en) | 2018-05-30 |
| WO2016130818A1 (en) | 2016-08-18 |
| AU2016219183B2 (en) | 2020-06-11 |
| US10221142B2 (en) | 2019-03-05 |
| AU2016219183A1 (en) | 2017-08-24 |
| EP3256450B1 (en) | 2020-12-02 |
| US20180016239A1 (en) | 2018-01-18 |
| EP3256450A1 (en) | 2017-12-20 |
| CA2975997A1 (en) | 2016-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3256450B1 (en) | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof | |
| ES2749713T3 (es) | Compuestos de indol e indazol sustituidos con 3-ciclohexenilo y ciclohexilo como inhibidores de RORgammaT y usos de los mismos | |
| JP6204985B2 (ja) | RORγT阻害剤としての3−アミノシクロアルキル化合物およびその使用 | |
| JP6411345B2 (ja) | RORγT阻害剤としてのN−アルキル化インドールおよびインダゾール化合物およびそれらの使用 | |
| AU2015253232B2 (en) | Substituted 4-phenylpiperidines, their preparation and use | |
| WO2023109883A1 (zh) | 一类芳杂环取代的化合物及其制备方法和用途 | |
| CN105051047B (zh) | 化学个体 | |
| WO2019158019A1 (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| EP3154976A2 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| EP3368539B1 (en) | Substituted indazole compounds as ror gamma t inhibitors and uses thereof | |
| EP3368516B1 (en) | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| CN113365696A (zh) | 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途 | |
| JP2018531958A (ja) | RORγT阻害薬としてのヘテロアリール置換安息香酸及びその使用 | |
| WO2017000125A1 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| HK1259662A1 (en) | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190124 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200512 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201027 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210121 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210622 |